The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia (CANALI)

NCT02474420 NA UNKNOWN

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2\* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Details

Lead sponsor	Kevin H.M. Kuo, MD, MSc, FRCPC
Phase	NA
Status	UNKNOWN
Enrolment	60
Start date	2015-06
Completion	2018-06

Conditions

• Beta-Thalassemia
• Iron Overload

Interventions

• Amlodipine
• Deferasirox

Primary outcomes

• Change in cardiac T2* — 12 months following randomization
  Change in cardiac T2\* as determined by MRI

Countries

Canada